RICHLAND, Wash.--(BUSINESS WIRE)--July 7, 2006--IsoRay, Inc. ("IsoRay") (OTCBB:ISRY - News), a medical technology company focusing on innovative treatment for prostate cancer and other solid cancer tumors through use of its proprietary Cesium-131 brachytherapy seeds, announced that it has withdrawn its application for a listing on the NASDAQ Capital Market. The application was withdrawn because IsoRay's stock did not meet the minimum bid requirement of $4 for more than ten trading days, and thus did not meet the listing requirements for the NASDAQ Capital Market. IsoRay plans to reapply for a listing on the NASDAQ Capital Market once its common stock regains its former pricing level.
